8432 results for "canc*"

in 23.84 milliseconds.

• Liquid Biopsy-informed Precision Oncology Study to Evaluate the Clinical Utility of Non-invasive Genomic Profiling for Cancer Treatment Selection

  This dataset pertains to the first planned analysis of an observational trial assessing the clinical utility of serial LB, combined with precision oncology recommendations by a molecular tumor board (MTB). Serial LBs utilized a clinically validated 33-gene panel next-generation sequencing (NGS) assay. Key eligibility criteria included age≥18years, ECOG performance status 0-1, and advanced/metastatic solid tumors with progression on ≥1 lines of therapy. 50 patients were enrolled between March 2023 and July 2024.

  Study EGAS50000002145

• Evolutionary dynamics in the decades preceding acute myeloid leukaemia

  Somatic evolution in ageing tissues underlies many cancers, yet the quantitative rules governing pre-cancerous evolution remain incompletely understood. This study exploits a collection of serial blood serum samples from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), collected annually from as early as 15 years before a diagnosis of acute myeloid leukaemia (AML), to provide a quantitative description of pre-cancerous evolutionary dynamics. Longitudinal samples from women who subsequently developed AML, alongside timepoint-matched samples from age-matched cancer-free controls, were sequenced using TETRIS-seq, a deep duplex error-corrected sequencing approach covering a custom panel of single-nucleotide variants and indels, mosaic chromosomal alterations, and chromosomal rearrangements associated with clonal haematopoiesis and AML. Combined with evolutionary modelling, these data quantify the acquisition ages and fitness effects of key driver events in AML development, characterise the clonal dynamics that precede diagnosis, and show that pre-leukaemic evolution is consistent with a small set of evolutionary rules balancing chance and determinism. The deposited data comprise raw paired-end FASTQ files for all sequenced samples.

  Study EGAS50000002168

• Alterations of whole genome and extrachromosomal circular cell-free DNA fragmentomes across the cancer care continuum

  The origins and properties of cancer-associated genetic changes in cell-free DNA (cfDNA) are not fully understood. Through genome-wide analyses of 1,807 samples from 1,064 patients across eight common cancer types, we identified extrachromosomal circular DNA (eccDNA) as a source of cfDNA fragments. Characterization of eccDNA-derived cfDNA fragments along with single base substitutions, small insertions and deletions, rearrangements, and phased variants in single cfDNA molecules, revealed differences between tumor tissues and cfDNA, with an increase in tumor-derived cfDNA alterations at epigenetically repressed regions and a decrease at active promoters. Combination of variant characteristics with individual error rates and machine learning analyses enabled tumor-informed and tumor-independent measures of circulating tumor DNA for early detection, detection of minimal residual disease, and for monitoring patients during therapy. The universal nature of eccDNA and other tumor-derived characteristics of cfDNA may be broadly useful for cancer detection.

  Study EGAS50000001331

• Cryptic mRNA Splicing in FLT3 Internal Tandem Duplications

  NGS analyses of genetic material from Acute Myeloid Leukemia cases harboring FLT3 Internal Tandem Duplications to investigate the occurrence of cryptic mRNA splicing.

  Study EGAS50000002156

• Standardized Molecular Detection of RET and Other Gene Fusions in Thyroid Cancer: A Two-Site Validation Study

  This study validated methods for detecting RET gene alterations in thyroid cancer using molecular testing across two institutions. It found that next-generation sequencing (NGS) reliably identified RET fusions, other gene fusions, and key mutations, with confirmation by FISH and RT-PCR. Results showed a high level of agreement between both institutions, demonstrating the accuracy and reproducibility of the testing methods. These findings support the use of standardized NGS-based protocols to identify patients who may benefit from RET-targeted therapies. 60 DNA and 60 RNA has been sequenced by targeted NGS

  Study EGAS50000001977

• VHIR Data Access Committee 2

  VHIR "Data Access CommitteeStandardized Molecular Detection of RET and Other Gene Fusions in Thyroid Cancer: A Two-Site Validation Study" Data Access Committee

  Dac EGAC50000001089

• Trascriptional profile of primary human NK cells after culture with A549 ß2m-/-

  This dataset comprises the transcriptional profiles of human Natural Killer (NK) cells obtained via bulk RNA sequencing approach. The NK cells were isolated from the peripheral blood mononuclear cells (PBMCs) of six healthy donors and subsequently cultured in the presence of A549 ß2m-/- cancer cells for a duration of 9 days. After culture, RNA was extracted using the QiagenRNeasy Plus Mini Kit (250) (Qiagen, 74136) according to manufacturer's instructions and sequencing was performed on two lanes of the Illumina NovaSeq 6000 instrument resulting in 51nt-long paired-end reads.

  Dataset EGAD50000000819

• RNA-seq fastq files

  RNA-seq fastq files for ER+ breast cancer patients before and after neo-adjuvant endocrine therapy

  Dataset EGAD50000001221

• ctDNA detection in preSBRT samples in oligoprogressing metastatic castration-resistant prostate cancer patients

  Targeted sequencing using the PCF-SELECT capture panel and the KAPA Hypercap workflow on DNA extracted from liquid biopsies to test if ctDNA detection in pretreatment samples associates with worse outcome to stereotactic body radiotherapy in oligoprogressing metastatic castration-resistant prostate cancer patients.

  Dataset EGAD50000003089

• Carcinoma of Unknown Primary (CUP): A comparison across tissue and liquid biomarkers (CUP-COMP) study

  The Carcinoma of Unknown Primary (CUP): A comparison across tissue and liquid biomarkers (CUP-COMP) study (NCT: NCT04750109) was sponsored by The Christie NHS Foundation Trust and funded by Innovate UK.

  Study EGAS50000001821